Skip to main content
Full access
New Research
Published Online: 1 September 2010

Prediction of Real-World Functional Disability in Chronic Mental Disorders: A Comparison of Schizophrenia and Bipolar Disorder

Abstract

Objective:

Schizophrenia and bipolar disorder are associated with multidimensional disability. This study examined differential predictors of functional deficits in the two disorders.

Method:

Community-dwelling individuals with schizophrenia (N=161) or bipolar disorder (N=130) were assessed with neuropsychological tests, symptom measures, and performance-based social and adaptive (i.e., everyday living skills) functional competence measures as well as three domains of real-world functioning: community and household activities; work skills; and interpersonal relationships. The authors used confirmatory path analysis to find the best-fitting models to examine the direct and indirect (as mediated by competence) prediction of the three domains of real-world functioning.

Results:

In all models for both groups, neurocognition's relationship with outcomes was largely mediated by competence. Symptoms were negatively associated with outcomes but unassociated with competence, with the exception of depression, which was a direct and mediated (through social competence) predictor in bipolar disorder. In both groups, neurocognition was related to activities directly and through a mediated relationship with adaptive competence. Work skills were directly and indirectly (through mediation with social competence) predicted by neurocognition in schizophrenia and entirely mediated by adaptive and social competence in bipolar disorder. Neurocognition was associated with interpersonal relationships directly in the schizophrenia group and mediated by social competence in both groups.

Conclusions:

Although there was greater disability in schizophrenia, neurocognition predicted worse functioning in all outcome domains in both disorders. These results support the shared role of neurocognition in bipolar disorder and schizophrenia in producing disability, with predictive differences between disorders in domain-specific effects of symptoms and social and adaptive competence.
Chronic mental disorders such as schizophrenia and bipolar disorder are among the most disabling illnesses worldwide (1, 2). Neurocognitive impairment is widely recognized as a primary factor in causing and maintaining disability in schizophrenia (3). Recent research has suggested that the relationship between neurocognition and real-world psychosocial outcomes is largely indirect, mediated by variables such as everyday living skills, social competence, social cognition, symptoms, intrinsic motivation, and metacognition (49). Thus, neurocognitive impairments are important predictors of functional impairments in schizophrenia, but most of the association with real-world behaviors flows through their relationship with higher-order adaptive skill sets.
In contrast to the large body of research on the neurocognitive and psychopathological determinants of functional outcomes in schizophrenia, substantially less information is available about the characteristics that contribute to the poor functional outcomes observed in bipolar disorder (10, 11). Two large prospective studies (12, 13) indicated that depressive symptoms are more frequent, and are correlated with greater functional impairments, than manic symptoms. Psychotic symptoms also contribute to disability, although they are not as prevalent in bipolar disorder as in schizophrenia (14). In recent years, research has indicated that impairments in sustained attention, verbal memory, and executive functioning appear to persist in the absence of mood episodes (15) and are related to indices of social and vocational functioning (1622). However, the relative and combined contributions of neurocognitive abilities and symptoms to either functional competence or community functioning are unclear.
Studies of functioning in bipolar disorder are limited by their reliance on subjective ratings of functioning, such as self-report measures, which have questionable validity in both disorders (23, 24) and may be influenced by current mood state (25). Furthermore, reliance on categorical milestones, such as employment, marriage, and independent living, may be limited by socioeconomic status and other contextual influences, such as availability of jobs, ethnicity, and disability compensation status (26, 27). Some societies provide such significant social support that ability measures have no correlation with outcome (28). Thus, investigators are increasingly relying on more objective measures, such as performance-based assessment of functional capacity and third-party ratings of functional behavior, to provide objective estimates of functional competence and functional outcomes, respectively. To date, results from studies of patients with schizophrenia suggest that these competence measures mediate the relationship between neurocognitive impairment and observer-rated functional impairment (29). The few studies that employed performance-based measures of functional competence in bipolar disorder (30, 31) converge to suggest that neurocognition is a stronger predictor of functional competence than symptoms. However, these studies were based on samples of middle-aged and elderly participants and did not assess relationships to real-world disability measures.
In this study, we extend to bipolar disorder our previous findings on schizophrenia, which suggested a relationship between neurocognition and real-world behavior that is largely mediated by functional competence. We also expand the schizophrenia literature to a more age-diverse sample of outpatients.

Method

Participants

To be included in the study, participants had to have a DSM-IV diagnosis of bipolar I disorder (the bipolar disorder group; N=130) or of schizophrenia or schizoaffective disorder (the schizophrenia group; N=161), based on a structured interview, and had to be living in the community. All participants were enrolled in a genetic study of schizophrenia and bipolar I disorder conducted by the Epidemiology-Genetics Program in Psychiatry at the Johns Hopkins University School of Medicine. Current clinical symptom severity and mood state were not among the inclusion or exclusion criteria.
The sample was restricted to full or mixed Ashkenazi Jewish ancestry (determined from the ancestry of four grandparents) in order to obtain a sample with high genetic homogeneity. Initial recruitment was conducted nationally through advertisements in newspapers and Jewish publications, talks given at community centers and synagogues, and the Epidemiology-Genetics Program web site (32). Patients participating in the genetic studies were directly assessed (largely in their own homes) by skilled clinicians (doctoral-level psychologists) using the Diagnostic Interview for Genetic Studies (33). Additional information from medical records, informant reports, and the Family Interview for Genetics Studies (http://zork.wustl.edu/nimh/home/m_interviews.html) was independently reviewed by at least two clinicians (a Ph.D.-level psychologist or a psychiatrist) before a consensus was formed on DSM-IV diagnoses and on various clinical indicators.
Recruitment and data collection methods were identical for both diagnostic groups. Participants from the parent genetics study were recruited via telephone and letter to participate in the present study and, after providing written informed consent, were assessed in their own homes by members of the original team of clinical examiners using a battery of commonly used neuropsychological tests.

Independent Variables

Neurocognitive composite score.

The neurocognitive battery included commonly used measures of verbal declarative memory, attention, verbal working memory, executive functioning, processing speed, and verbal fluency. We calculated a composite neurocognitive score using equally weighted standardized scores (z scores; mean=0, SD=1) that were derived from normative data from the manuals for each instrument. The composite neurocognitive score included eight variables: total learning from trials 1 through 5 on the Rey Auditory Verbal Learning Test (34), total time to complete Part A and Part B of the Trail Making Test (35), number of correct responses on the letter-number span test from the WAIS (36), perseverative errors standard score from the 64-card computerized Wisconsin Card Sorting Test (37), number of correct responses on the WAIS digit symbol coding test, total unique correct responses on a semantic fluency test (38), and dr (a signal detection measure) from the Continuous Performance Test–Identical Pairs Version, 4-digit condition (39). The Cronbach alpha value for the composite score was 0.84, indicating good internal consistency. We also examined differences between groups in estimated premorbid intelligence using the reading subtest of the Wide-Range Achievement Test, 3rd Edition (40).

Psychopathology measures.

We assessed depressive symptoms with the Beck Depression Inventory, 2nd edition (BDI; 41). A total depressive symptoms score is created by summing the 21 items of the instrument (range=0 to 63).
The Profile of Mood States–Bipolar Form (42) provided an index of the severity of manic symptoms. This self-report of current mood asks the participant to rate 72 items on a 4-point Likert scale (“much unlike this,” “slightly unlike this,” “slightly like this,” and “much like this”). Raw scores were converted to T scores from normative data found in the manual. The total scale T score was used as the mania variable, with higher scores indicating more severe manic symptoms. (The T scores are presented relative to the psychiatric outpatient sample, not a healthy comparison sample.)
Severity of positive and negative symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS; 43). This 30-item scale, which contains seven items measuring positive symptoms, seven items measuring negative symptoms, and 16 items measuring general aspects of psychopathology, was completed after a structured interview by a psychologist and a structured interview with an informant. We used the positive and negative domains from the empirically derived five-factor model of the PANSS (44).

Proposed Mediators

We examined adaptive competence and social competence independently to observe whether they contributed differentially to the prediction of diverse outcomes. These measures had overlap (r2=0.37) consistent with the correlation between the University of California San Diego [UCSD] Performance-Based Skills Assessment (UPSA; 45) and neurocognitive performance in our previous research (4, 5). The magnitude of this correlation suggests that these two ability areas are related but separable areas of functional skills.

Adaptive competence.

We refer to adaptive competence as those instrumental skills that are important for functioning independently (46). An adaptive functional competence variable was created from an equally weighted composite of the UCSD Performance-Based Skills Assessment–Brief Version (UPSA-B; 45) and the advanced finances test from the Everyday Functional Battery (EFB; 47); we call this composite measure the UPSA-B/EFB. In the UPSA-B, respondents are asked to role play tasks in two areas of everyday functioning: communication and finances. The total raw score ranges from 0 to 20. In the advanced finances test, participants perform higher-level financial management skills than in the UPSA, including depositing a check, paying three bills (including only a portion of the credit card bill in order to leave money in the account), and balancing a checkbook. Raw scores range from 0 to 17. The composite adaptive functional competence variable had adequate internal consistency (Cronbach's alpha=0.87). It was converted to a standard score ranging from 0 to 100, with higher scores indicating better adaptive competence.

Social competence.

Social competence (i.e., paralinguistic and verbal behaviors necessary for communication) was assessed with the Social Skills Performance Assessment (48). After a brief practice, participants initiate and maintain a conversation for 3 minutes in each of two situations: greeting a new neighbor and calling a landlord to request a repair for a leak that has gone unfixed. Affect and grooming are rated in person by the examiner; all other variables, such as interest, fluency, clarity, focus, negotiation ability, submissiveness/persistence, and social appropriateness, were rated via audiotape by an off-site trained rater who was unaware of the study design, diagnosis, and all other data. We used the mean item score on these variables for both scenes as the social competence variable, with higher scores indicating better social competence.

Outcome Variables

The Specific Level of Functioning Scale (49) was used to rate real-world functional outcome. This 43-item observer-rated scale measures the following domains: interpersonal relationships (e.g., initiating, accepting, and maintaining social contacts; effectively communicating), participation in community and household activities (shopping, using the telephone, paying bills, using public transportation), and work skills (e.g., employable skills, level of supervision required to complete tasks, punctuality, ability to stay on task and complete tasks). Note that the work skills domain comprises behaviors important for vocational performance but is not a rating of behavior during employment. Ratings by the third-party informant are made on the basis of the amount of assistance required to perform real-world skills or frequency of the behavior. Raters were selected who were familiar with the participant's functioning (e.g., family members, friends, case managers). If such individuals were unavailable, the examiner rated this information from his or her own observations of and interactions with the participant. Twelve percent of the schizophrenia group and 13% of the bipolar disorder group were rated by the examiner on the Specific Level of Functioning Scale. We ran multivariate analyses of variance for each group to determine whether there were differences on the three variables of instrument for those who were rated by an examiner. There were no statistically significant differences for either group on any of the subscales or demographic variables (all p values >0.05).

Statistical Analysis

We tested the direct and indirect predictors of the Specific Level of Functioning Scale real-world outcome domains with confirmatory path analyses in the separate diagnostic groups. Based on previous research (8, 9), we predicted that neurocognition, the empirically derived positive and negative symptom domains, and the total scores from the BDI and the Profile of Mood States–Bipolar Form as exogenous variables (i.e., variables that are not predicted directly by other variables) would predict each of the real-world outcome domains. The two competence measures, the UPSA-B/EFB (adaptive competence) and the Social Skills Performance Assessment (social competence), were hypothesized as mediating neurocognition but not symptom variables.
The final models were developed within each sample through an iterative procedure in which statistically nonsignificant paths with the smallest contribution to the outcome variable were sequentially eliminated from a saturated model (in which all variables are interrelated) until the best-fitting model was identified, defined by three different goodness-of-fit statistics: the model chi-square, the comparative fit index (CFI), and the root mean square error of approximation (RMSEA). A good-fitting model is reflected by nonsignificant chi-square tests, a CFI greater than 0.90, and an RMSEA less than 0.08. The chi-square test is a comparison of the observed covariance matrix to the covariance matrix of the final model. The CFI compares the final model with an “independence model” and indicates the percent to which covariation in the data is replicable. The independence model is a null model that assumes that all variables are uncorrelated with the dependent variable. The RMSEA is a model fit measure that accounts for model complexity, thus promoting the most parsimonious model by considering degrees of freedom.
Diagnostic comparisons of the strength of neurocognition's direct and mediated path coefficients for the competence and real-world performance measures were performed by testing for the significance of the difference between coefficients. The total causal effects for the real-world measures were determined with effects decomposition, where indirect effects are the factor of the coefficient from neurocognition to the competence measure and the competence measure to real-world behavior. The total causal effect is the sum of all indirect effects and the direct effect.

Results

The demographic and clinical characteristics, test performance results, and functional ratings of the two groups are presented in Table 1.
TABLE 1. Demographic and Clinical Characteristics, Test Performance Results, and Functional Ratings of Patients With Schizophrenia or Bipolar I Disorder
VariableaSchizophrenia Group (N=161)Bipolar Disorder Group (N=130)Analysis
 MeanSDRangeMeanSDRangeFdfp
Age at assessment (years)49.99.616–7848.414.318–801.01, 2900.300
Age at first mental health treatment (years)20.35.85–4123.38.97–5410.51, 2530.001
Education (years)14.15.94–2014.88.68–200.71, 2900.410
Neurocognition measures         
    WRAT-3 reading recognition standard score100.711.671–120107.39.168–12027.41, 290< 0.001
    Rey Auditory Verbal Learning Test, trials 1–5−1.741.3−5.6 to 2.1−0.591.2−3.8 to 2.153.71, 285< 0.001
    Trail Making Test, Part A−2.351.7−5.0 to 0.8−1.391.6−5.0 to 1.422.61, 290< 0.001
    Trail Making Test, Part B−1.462.1−5.0 to 1.5−0.271.5−5.0 to 2.127.61, 290< 0.001
    WAIS letter-number sequencing test−0.591.1−3.0 to 2.0−0.011.1−3.0 to 3.020.21, 285< 0.001
    WAIS digit symbol test−1.000.8−2.6 to 1.0−0.201.1−2.6 to 3.045.41, 290< 0.001
    Semantic fluency test−0.731.2−3.0 to 3.4−0.081.2−2.8 to 3.532.21, 289< 0.001
    Wisconsin Card Sorting Test, perseverative errors−1.051.0−3.1 to 2.1−0.881.0−3.1 to 3.11.91, 278< 0.160
    Continuous Performance Test (d′)−1.611.2−5.9 to 1.2−0.911.1−3.4 to 1.522.41, 286< 0.001
    Neurocognitive composite score−1.330.9–3.6 to 0.51−0.540.82.7–1.054.31, 290< 0.001
Psychopathology symptom measures         
    PANSS negative domain, mean item score2.31.11.0–6.01.50.61.0–4.371.81, 290< 0.001
    PANSS positive domain, mean item score2.51.21.0–5.41.40.71.0–4.089.31, 290< 0.001
    Beck Depression Inventory10.99.40–419.810.20–451.11, 2820.290
    Profile of Mood States–Bipolar Form (T score)43.06.930.0–61.343.68.530.6–67.00.11, 2600.720
Functional and social competence measures         
    UPSA-B15.33.93–2017.72.44.0–2040.31, 288< 0.001
    Advanced finances test8.54.40–1311.32.60–1338.81, 282< 0.001
    Social Skills Performance Assessment3.91.11.1–5.04.30.43.1–5.015.81, 259< 0.001
Real-world behavior measures         
    Specific Level of Functioning Scale         
        Interpersonal subscale4.00.91.0–5.04.40.62.1–5.017.81, 291< 0.001
        Activities subscale4.30.71.6–5.04.60.42.0–5.025.61, 291< 0.001
        Work skills subscale3.71.01.0–5.04.30.81.6–5.035.61, 291< 0.001
 N% N% χ2dfp
Female6137.9 6449.2 3.710.052
Ever married3723 7154.6 32.71< 0.001
First-degree family member with schizophrenia2012.4 21.5 8.51< 0.001
First-degree family member with bipolar disorder42.4 4132 25.41< 0.001
Psychotropic medications         
    Conventional antipsychotic3018.6 64.6 13.31< 0.001
    Atypical antipsychotic13382.6 5844.6 46.01< 0.001
    Lithium148.7 4030.8 23.11< 0.001
    Anticonvulsant4729.2 6852.3 16.01< 0.001
    Selective serotonin reuptake inhibitor6439.8 4232.2 1.710.190
    Tricyclic antidepressant42.5 21.5 0.310.570
    Anxiolytic3018.6 2015.4 0.510.460
    Anticholinergic2113 10.8 15.51< 0.001
    No psychotropic medications74.3 1713.1 7.210.007
a
Neurocognition scores are represented as z scores with mean=0 and SD=1 (higher scores indicate better performance) transformed relative to age-corrected normative data found in the manuals of each instrument, except the WRAT-3 reading score, for which mean=100 and SD=15 (higher scores indicate better performance) based on the age-corrected normative data in the instrument's manual. For all psychopathology symptom variables, higher scores indicate more severe symptoms. For neurocognition, competence, and real-world behavior scores, higher scores indicate better performance. WRAT-3=Wide-Range Achievement Test, 3rd Edition; WAIS=Wechsler Adult Intelligence Scale; PANSS=Positive and Negative Syndrome Scale; UPSA-B=UCSD Performance-Based Skills Assessment–Brief Version.
The final models produced adequate fit statistics for both groups across all three real-world outcome domains (Table 2). Neurocognition was associated with both competence variables, but only depressive symptom severity was associated with either competence variable. In both groups, neurocognition was related to activities (Figure 1; schizophrenia group, R2=0.53; bipolar disorder group, R2=0.39) directly and through a mediated relationship with adaptive competence. Negative symptoms and depressive symptom severity were negatively associated with activities in the schizophrenia group, and positive, negative, and manic symptoms were negatively associated with activities in the bipolar disorder group. Work skills (Figure 2; schizophrenia group, R2=0.40; bipolar disorder group, R2=0.30) were directly and indirectly (through mediation with social competence) predicted by neurocognition in the schizophrenia group, and neurocognition's association with work skills in the bipolar disorder group was mediated entirely by adaptive and social competence. Positive and negative symptoms were negatively associated with work skills in both groups; depressive symptoms further predicted poor work skills in the bipolar disorder group. Interpersonal relationships (Figure 3; schizophrenia group, R2=0.53; bipolar disorder group, R2=0.46) were predicted indirectly (through social competence) by neurocognition in both groups and directly by neurocognition, positive symptoms, and negative symptoms in the schizophrenia group. In the bipolar disorder group, interpersonal relationships were predicted by manic symptoms and by depressive symptoms, the latter of which had both a direct and a mediated (through social competence) relationship.
TABLE 2. Fit Statistics for the Independence Models and Final Models for Relationships Among Performance Variables, Functional Ratings, and Real-World Outcomes of Patients With Schizophrenia or Bipolar I Disordera
Outcome Measure and ModelSchizophrenia GroupBipolar Disorder Group
χ2dfpCFIRMSEA90% CIχ2dfpCFIRMSEA90% CI
Interpersonal functioning            
    Final model11.680.170.9910.030.0–0.0816.2130.230.9670.040.0–0.09
    Independence model328.121< 0.0010.0000.220.20–0.2416128< 0.0010.0000.190.16–0.22
Activities            
    Final model8.970.251.0000.000.0–0.1215.7130.271.0000.000.0–0.11
    Independence model261.815< 0.0010.0000.320.28–0.3515928< 0.0010.0000.220.18–0.25
Work skills            
    Final model9.580.300.9760.040.0–0.0913.4110.270.9940.020.0–0.11
    Independence model16921< 0.0010.0000.210.18–0.2415928< 0.0010.0000.190.16–0.21
a
CFI=comparative fit index; RMSEA=root mean square error of approximation.
FIGURE 1. Prediction of Community and Household Activities in Schizophrenia and Bipolar Disordera
a Bidirectional arrows represent correlated exogenous variables (variables without direct predictors), represented as correlation coefficients. Unidirectional arrows represent regression beta weights. Variance accounted for is indicated within each of the endogenous variables (those with direct predictors).
FIGURE 2. Prediction of Work Skills in Schizophrenia and Bipolar Disordera
a Bidirectional arrows represent correlated exogenous variables (variables without direct predictors), represented as correlation coefficients. Unidirectional arrows represent regression beta weights. Variance accounted for is indicated within each of the endogenous variables (those with direct predictors).
FIGURE 3. Prediction of Interpersonal Behavior in Schizophrenia and Bipolar Disordera
a Bidirectional arrows represent correlated exogenous variables (variables without direct predictors), represented as correlation coefficients. Unidirectional arrows represent regression beta weights. Variance accounted for is indicated within each of the endogenous variables (those with direct predictors).
The test for significant differences between coefficients revealed significant differences between the two diagnostic groups in the strength of the relationship of neurocognition with competence measures and real-world behavior. In the activities domain, the direct relationship of neurocognition was not significantly different between the groups, but the total causal effect (direct plus indirect effects) was significantly larger in the schizophrenia group (standardized regression coefficient β=0.47) compared with the bipolar disorder group (β=0.29) (p=0.038). In this model, the strength of the path from neurocognition to adaptive competence was stronger in schizophrenia (p=0.006). Neurocognition was not a direct predictor of work skills in the bipolar disorder group, and its total causal effect in this group (β=0.20) was lower than in the schizophrenia group (β=0.36), but this difference did not reach statistical significance (p=0.07). The relationship of neurocognition with social competence was not significantly different between diagnostic groups (p=0.14). Interpersonal behavior was not directly predicted by neurocognition in the bipolar disorder group, and its total causal effect (β=0.027) was lower than in the schizophrenia group (β=0.29) (p=0.01).

Discussion

The results of this study expand previous findings that modeled the direct and indirect relationships among measures of neurocognition, symptoms, functional competence, and everyday outcomes in patients with schizophrenia and show further that the model largely generalizes to patients with bipolar disorder. The relationships between neurocognition and functioning include both direct relationships and relationships mediated by adaptive and social competence. In contrast, clinical symptoms (with the exception of depressive symptoms) were related to functioning in the community but not with competence, which suggests that the effects of positive, negative, and manic symptoms on everyday behaviors might occur at a postcompetence level, not affecting the ability to perform skilled acts yet influencing the likelihood of performing them. These findings converge to suggest that we might observe persistent functional disability in patients with schizophrenia or bipolar disorder even after they cross traditional thresholds for treatment success (such as a given percentage reduction in positive symptom severity) as a result of neurocognitive and skill deficits. Conversely, even if a patient acquires certain skills but continues to experience mild levels of core (positive and negative) and nonspecific (depressed) symptoms, changes in real-world behavior might lag or not manifest at all.
Our results suggest that the paths from clinical factors to real-world disability are consistent in a number of important ways between patients with schizophrenia and those with bipolar disorder, even when there are differences between disorders in the severity of real-world deficits. Neurocognition clearly has an important role in functional outcomes across both disorders, although the direct and total effects are larger in schizophrenia. In contrast to a previous study with older schizophrenia patients (4), in this study we found more evidence for direct effects of neurocognition on work skills and interpersonal behavior, perhaps related to the greater age range of our sample or the larger sample size. To our knowledge, no previous study has examined whether functional competence measures mediate the link between neurocognition and disability in bipolar disorder. Our data suggest that the mediation role of these measures in bipolar disorder may actually be more pronounced than in schizophrenia, with most of the relationship between cognition and real-world outcomes mediated by competence. Thus, the path from neurocognitive deficit to functional disability is stronger and more direct in schizophrenia but still quite relevant in bipolar disorder.
The role of symptoms in predicting disability was significant, but it was generally unmediated by competence measures and was somewhat different in bipolar disorder compared to schizophrenia. Similar to previous studies—and not surprising given their diagnostic importance—depressive and manic symptoms were associated with real-world functional performance deficits in bipolar disorder, with manic symptoms having an inverse relationship with activities in the home and community, depression negatively associated with work skills, and both types of mood symptoms associated with poorer interpersonal behavior. Similar to previous reported findings on bipolar disorder (12, 13), depressive symptoms were stronger predictors of poor outcomes than manic symptoms. The positive symptom associations with outcomes in this bipolar disorder sample might indicate that positive symptoms, although less frequent and severe in bipolar disorder, are more disruptive when present in this condition, which typically has a more cyclical manifestation of psychosis. Negative symptoms are infrequently reported in the bipolar disorder literature, which limits our ability to interpret the present findings. It is unlikely that the relationship is an artifact of measurement overlap with depressive symptoms; total scores for depression and negative symptoms had a small, nonsignificant relationship in this sample, and previous work (50) has indicated that measurement of depressive symptoms with the BDI does not substantially overlap with negative symptoms.
The present findings are supported by other reports that suggest that depressive symptoms are an important predictor of disability in bipolar disorder (12, 51). An interesting deviation across the two diagnostic groups was the path from symptoms of depression to real-world outcomes. In bipolar disorder, but not schizophrenia, depression was associated with social competence, and its relationship with interpersonal behavior and work skills was partially mediated by this relationship. Thus, in bipolar disorder, depressive symptoms may serve as a potential rate limiter of real-world behavior and also as a phasic suppressor of social skills. Alternatively, poor social skills may produce a vulnerability to depression. It would be important for future research to investigate the intraindividual trajectories of social skills and depression in bipolar disorder to understand the direction of causal relationships. Such knowledge would be useful in adapting rehabilitation approaches to bipolar disorder.
There are several limitations to this study. The sample was restricted to a culturally homogeneous group. Participants were outpatients and on average were experiencing mild symptoms. Therefore, the generalizability of these findings to ethnically diverse populations, to inpatients, and to more acutely ill patients is limited. Some studies (e.g., reference 20) have demonstrated relationships of specific neurocognitive domains to functional deficits that differed by diagnosis; although our sample size was considerable, it was not sufficiently powered to evaluate each neurocognitive test individually in the statistical procedure used. For some individuals with bipolar disorder, there will be a ceiling effect for the functional competence and outcome domains, and future research should determine how sensitive these and other measures are for the more subtle functional deficits. Additionally, it will be important to assess more domains of functioning and to continue to search for optimal methods for assessing disability in chronic mental disorders. As in efforts to refine our assessment of outcomes in schizophrenia (52), our understanding of the severity and predictors of disability in bipolar disorder would be enhanced by similar endeavors. Finally, this study was cross-sectional; further work examining the sources of intraindividual variability in functional abilities over time is needed to ascertain causal effects of illness characteristics on long-term functioning outcomes.
In summary, our findings indicate that multivariate path models linking neurocognitive ability, functional competence, and symptoms with real-world functional performance confirm previous models in schizophrenia and generalize to bipolar disorder. Disability is multiply determined, with the effect of neurocognition mediated by functional capacity and a separable and more direct effect of symptoms. Differences between schizophrenia and bipolar disorder lie largely in the strength of the relationships and which symptoms most influence disability, and our study reaffirms the broad debilitating role of bipolar depression in maintaining disability. These results suggest that recent advances in measurement of cognitive and functional abilities in schizophrenia may be quite relevant to measurement of disability and related rehabilitative efforts in bipolar disorder. As opposed to schizophrenia, there has been little emphasis on pharmacological or nonpharmacological cognitive remediation in bipolar disorder, and there have been few examples of rehabilitative programs aimed at functional skills in patients with bipolar disorder (11). Our results support the suggestion that models for cognitive rehabilitation under way in schizophrenia (53) should be adapted for bipolar disorder (54).

Footnote

Received Oct. 5, 2009; revision received Jan. 29, 2010; accepted Feb. 25, 2010

References

1.
Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global Burden of Disease and Risk Factors. Washington, DC, World Bank, 2006
2.
Ormel J, Petukhova M, Chatterji S, Aguilar-Gaxiola S, Alonso J: Disability and treatment of specific mental and physical disorders. Br J Psychiatry 2008; 192:368–375
3.
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321–330
4.
Bowie CR, Reichenberg A, Patterson TL, Heaton RK, Harvey PD: Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am J Psychiatry 2006; 163:418–425
5.
Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD: Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 2008; 63:505–511
6.
Sergi MJ, Rassovsky Y, Nuechterlein KH, Green MF: Social perception as a mediator of the influence of early visual processing on functional status in schizo-phrenia. Am J Psychiatry 2006; 163:448–454
7.
Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH: Symptoms as mediators of the relationship between neurocognition and functional out-come in schizophrenia: a meta-analysis. Schizophr Res 2009; 113:189–199
8.
Nakagami E, Xie B, Hoe M, Brekke JS: Intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia: testing mediator and moderator effects. Schizophr Res 2008; 105:95–104
9.
Koren D, Seidman LJ, Goldsmith M, Harvey PD: Real-world cognitive-and metacognitive-dysfunction in schizophrenia: a new approach for measuring (and remediating) more “right stuff.” Schizophr Bull 2006; 32:310–326
10.
Green MF: Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67:e12
11.
Wingo AP, Harvey PD, Baldessarini RJ: Neurocognitive impairment in bipolar disorder patients: functional implications. Bipolar Disord 2009; 11:113–125
12.
Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB: Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005; 62:1322–1330
13.
Post R, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Keck PE, McElroy SL, Kupka R, Nolen WA, Grunze H, Walden J: An overview of recent findings of the Stanley Foundation Bipolar Network (part I). Bipolar Disord 2003; 5:310–319
14.
Huxley N, Baldessarini RJ: Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007; 9:183–196
15.
Bearden CE, Hoffman KM, Cannon TD: The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disord 2001; 3:106–150
16.
Altshuler L, Tekell J, Biswas K, Kilbourne AM, Evans D, Tang D, Bauer MS: Executive function and employment status among veterans with bipolar disorder. Psychiatr Serv 2007; 58:1441–1447
17.
Altshuler LL, Bearden CE, Green MF, van Gorp W, Mintz J: A relationship between neurocognitive impairment and functional impairment in bipolar disorder: a pilot study. Psychiatry Res 2008; 157:289–293
18.
Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Cole S, Yolken RH: Association between cognitive functioning and employment status of persons with bipolar disorder. Psychiatr Serv 2004; 55:54–58
19.
Jaeger J, Vieta E: Functional outcome and disability in bipolar disorders: ongoing research and future directions. Bipolar Disord 2007; 9:1–2
20.
Laes JR, Sponheim SR: Does cognition predict community function only in schizophrenia? a study of schizophrenia patients, bipolar affective disorder pa-tients, and community control subjects. Schizophr Res 2006; 84:121–131
21.
Martinez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M, Malhi GS, Gonzalez-Pinto A, Daban C, Alvarez-Grandi S, Fountoulakis K, Kaprinis G, Tabares-Seisdedos R, Ayuso-Mateos JL: Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007; 9:103–113
22.
Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, Martinez-Aran A, Salazar-Fraile J, Selva-Vera G, Rubio C, Mata I, Gomez-Beneyto M, Vieta E: Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord 2008; 109:286–299
23.
Bowie CR, Twamley EW, Anderson H, Halpern B, Patterson TL, Harvey PD: Self-assessment of functional status in schizophrenia. J Psychiatr Res 2007; 41:1012–1018
24.
Burdick KE, Endick CJ, Goldberg JF: Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res 2005; 136:43–50
25.
Dean BB, Gerner D, Gerner RH: A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin 2004; 20:139–154
26.
Drake RE, Fox TS, Leather PK, Becker DR, Musumeci JS, Ingram WF, McHugo GJ: Regional variation in competitive employment for persons with severe mental illness. Adm Policy Ment Health 1998; 25:493–504
27.
Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman JCATIE Study Investigators Group: Barriers to employment for people with schizophrenia. Am J Psychiatry 2006; 163:411–417
28.
Harvey PD, Helldin L, Bowie CR, Heaton RK, Olsson A-K, Hjärthag F, Norlander T, Patterson TL: Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. Am J Psychiatry 2009; 166:821–827
29.
Twamley EW, Doshi RR, Nayak GV, Palmer BW, Golshan S, Heaton RK, Patterson TL, Jeste DV: Generalized cognitive impairments, ability to perform everyday tasks, and level of independence in community living situations of older patients with psychosis. Am J Psychiatry 2002; 159:2013–2020
30.
Gildengers AG, Butters MA, Chisholm D, Rogers JC, Holm MB, Bhalla RK, Seligman K, Dew MA, Reynolds CF, Kupfer DJ, Mulsant BH: Cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Am J Geriatr Psychiatry 2007; 15:174–179
31.
Depp CA, Cain AE, Palmer BW, Moore DJ, Eyler LT, Lebowitz BD, Patterson TL, Jeste DV: Assessment of medication management ability in middle-aged and older adults with bipolar disorder. J Clin Psychopharmacol 2008; 28:225–229
32.
Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, Steel G, Nestadt G, Liang KY, Huganir RL, Valle D, Pulver AE: Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 2005; 77:918–936
33.
Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T: Diagnostic Interview for Genetic Studies: rationale, unique features, and training. Arch Gen Psychiatry 1994; 51:849–859
34.
Schmidt M: Rey Auditory and Verbal Learning Test: A Handbook. Los Angeles, Western Psychological Services, 1996
35.
Reitan RM, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, 2nd ed. Tucson, Ariz, Neuropsychology Press, 1993
36.
Wechsler D: WAIS-IV: Technical and Scoring Manual. San Antonio, Tex, Pearson, 2008
37.
Heaton RK, Chellune CJ, Talley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test Manual: Revised and Expanded. Odessa, Fla, Psychological Assess-ment Resources, 1993
38.
Spreen O, Strauss E: A Compendium of Neuropsychological Tests and Norms, 2nd ed. New York, Oxford University Press, 1998
39.
Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L: The Continuous Performance Test, Identical Pairs Version (CPT-IP), I: new findings about sustained attention in normal families. Psychiatry Res 1988; 26:223–238
40.
Jastak S: Wide-Range Achievement Test, 3rd ed. San Antonio, Tex, Wide Range, Inc, 1993
41.
Beck AT, Steer RA, Brown GK: Manual for the Beck Depression Inventory-II. San Antonio, Tex, Psychological Corp, 1996
42.
Lorr M, McNair DM: Manual: Profile of Mood States-Bipolar Form. San Diego, Educational and Industrial Testing Service, 1968
43.
Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–276
44.
White L, Harvey PD, Opler L, Lindenmayer JP: Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: a multisite, multimodel evaluation of the factorial structure of the Positive and Negative Syndrome Scale. Psychopathology 1997; 30:263–274
45.
Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV: UCSD Performance-Based Skills Assessment: development of a new measure of everyday func-tioning for severely mentally ill adults. Schizophr Bull 2001; 27:235–245
46.
Mausbach BT, Bowie CR, Harvey PD, Twamley EW, Goldman SR, Jeste DV, Patterson TL: Usefulness of the UCSD Performance-Based Skills Assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res 2008; 42:320–327
47.
Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I(HNRC Group): The impact of HIV-associated neuro-psychological impairment on everyday functioning. J Int Neuropsychological Soc 2004; 10:317–331
48.
Patterson TL, Moscona S, McKibbin CL, Davidson K, Jeste DV: Social skills performance assessment among older patients with schizophrenia. Schizophr Res 2001; 48:351–360
49.
Schneider LC, Struening EL: SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr 1983; 6:9–21
50.
Chemerinski E, Bowie C, Anderson H, Harvey PD: Depression in schizophrenia: methodological artifact or distinct feature of the illness? J Neuropsychia-try Clin Neurosci 2008; 20:431–440
51.
Simon GE, Bauer MS, Ludman EJ, Operskalski BH, Unutzer J: Mood symptoms, functional impairment, and disability in people with bipolar disorder: specific effects of mania and depression. J Clin Psychiatry 2007; 68:1237–1245
52.
Leifker FR, Patterson TL, Heaton RK, Harvey PD: Validating measures of real-world outcome: the results of the VALERO Expert Survey and RAND Panel. Schizophr Bull (Epub ahead of print, Jun 12, 2009)
53.
Green MF, Nuechterlein KH: The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr Res 2004; 72:1–3
54.
Miklowitz DJ, Otto MW, Frank E, Reilly-Harrington NA, Kogan JN, Sachs GS, Thase ME, Calabrese JR, Marangell LB, Ostacher MJ, Patel J, Thomas MR, Araga M, Gonzalez JM, Wisniewski SR: Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial. Am J Psychiatry 2007; 164:1340–1347

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1116 - 1124
PubMed: 20478878

History

Received: 5 October 2009
Revision received: 29 January 2010
Accepted: 25 February 2010
Published online: 1 September 2010
Published in print: September 2010

Authors

Details

Christopher R. Bowie, Ph.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Colin Depp, Ph.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
John A. McGrath, M.A.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Paula Wolyniec, M.A.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Brent T. Mausbach, Ph.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Mary H. Thornquist, Ph.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
James Luke, Psy.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Thomas L. Patterson, Ph.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Philip D. Harvey, Ph.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.
Ann E. Pulver, Sc.D.
From the Departments of Psychology and Psychiatry, Queen's University; the Department of Psychiatry, University of California San Diego; the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine; and the Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine.

Notes

Address correspondence and reprint requests to Dr. Bowie, Department of Psychology, 62 Arch St., Queen's University, Kingston, ON K0H 1S0, Canada; [email protected] (e-mail).

Funding Information

Dr. Bowie has served on a scientific advisory board and as a consultant for Abbott Pharmaceuticals. Dr. Harvey has served as a consultant to Abbott, Dainippon Sumitomo Pharma America, Eli Lilly, Johnson & Johnson, Merck, Shire Pharma, and Solvay and has received grant support from AstraZeneca. All other authors report no financial relationships with commercial interests.Supported by NIMH grant R01MH079784 to Dr. Pulver, grant RO1MH78775 to Dr. Harvey, and grant R01MH078737 to Dr. Patterson.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share